Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
about
Chemotherapy-induced peripheral neurotoxicity: a critical analysisSingle agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyUpdate on the optimal use of bortezomib in the treatment of multiple myelomaBortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survivalPrimary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studySubclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation densityAcetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin OncologySchwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathyDiagnosis and management of neuropathies associated with plasma cell dyscrasias.Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibPathological crystallization of human immunoglobulins.Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapyNeuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.Arsenic trioxide rewires mantle cell lymphoma response to bortezomibImmune modulation therapy in the management of bortezomib-induced peripheral neuropathy.A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaPharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathyPhytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Bortezomib-induced painful neuropathy in patients with multiple myeloma.Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice.Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Guidelines for supportive care in multiple myeloma 2011.Bortezomib for previously untreated multiple myeloma.Genomic stratification of multiple myeloma treated with novel agents.Bortezomib for previously untreated multiple myeloma.New Treatment Approaches for Older Adults with Multiple Myeloma.
P2860
Q27010318-269E176F-B3E1-480D-A74A-99DA912300CDQ33389026-885DD320-BDC2-4DAE-8DCC-C51C68CB9677Q33389111-809283A8-87EF-4701-8F1C-D8C31FD7C807Q33391566-411ED8AA-8DC1-4E92-A67D-A2620E6570CAQ33422017-48761E06-50AE-4698-B28F-22DA7B50D3EEQ33440007-7A90F650-39F4-4256-9B05-4ED59B105162Q33831838-6177BAB1-DE73-4698-AB6A-7EB5205C1AB8Q34063353-D64978B3-EC65-4B1E-9B1B-47B477A6C4DFQ34213649-678936BB-C675-4F2B-B49E-9AB12DB29FC1Q34226021-24180506-73C2-4D51-8C16-D51B1FC8839BQ34245549-D30DE616-D95D-420F-AA2C-A2EFE65AA5DDQ34344053-FB0A4DD8-64CD-4CD4-8A0A-58F92D30AFA6Q34555067-CECC7BD5-E2B6-4328-802A-18788DA8C3F8Q34608271-80CE102E-4A8F-4BFE-80A5-77ACF9E8EE1CQ34993904-1EEDCB98-6F99-4E18-A315-F070A6003181Q35072963-87D0D4C4-D6C8-4FA2-AF13-45C94D174972Q35188312-E97B82C5-8044-4CC2-9D61-4C76069A1D15Q35528750-B0CF3EDC-BCD0-437D-98A9-688DCD8AB740Q35675837-FEEFC93B-756E-4532-B777-C94C35D436D9Q35802414-3ECC4C74-A4C0-4850-AE96-DEB313DFA73FQ35905929-C4122C79-D5B2-4345-AD8F-5A5EAF7CA1E8Q36170645-DD58BBEB-6A7A-4BF9-90F8-2BA7F6907907Q36251560-8A34F8C0-0856-4E80-AF57-B7E0C138054DQ36302859-18465734-D87C-408E-9FAE-4172FD12BADAQ36358595-57099A71-7E99-4364-A930-30729E303E5BQ36444453-699DD38E-5D79-4FF9-8054-80AC121E625AQ36671445-FBB9FFE5-F3C6-4B5C-BB20-57D164DC3649Q37064721-8345BB04-CAC5-40B4-9161-9CC7B71ADEE8Q37216797-8805C181-C8D0-43A8-82EC-4A4859040FF2Q37275721-CE7AE8DB-1628-4550-896F-FF80C26B3AC9Q37399781-CEDBAFB7-42E2-47E8-98AF-EB7FC87515B1Q37601865-5037CFD6-EAD2-4364-89AC-9CAF71EEA970Q37734620-C7227BBA-7E59-4D9A-AB3F-F8789A7D788AQ37760210-CF9996C2-C982-4527-A4D2-969FBF0CF555Q37842346-228E206B-92C7-4933-B5C0-6C95BB338A08Q37868637-E5C5C701-558F-4DFE-A111-F6A4585806D3Q37908155-38DDFD33-45CC-4C75-9347-39E0BC22CC10Q37913346-005CB53E-BE30-4BA5-A0E1-CC66D83E79E2Q37937699-8E5BCBC5-2EA5-45DB-824C-86E272F40454Q38048281-5FA46C5E-781E-401B-BBE9-4FD90A7D71AB
P2860
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Single-agent bortezomib in pre ...... with response and neuropathy.
@en
Single-agent bortezomib in pre ...... with response and neuropathy.
@nl
type
label
Single-agent bortezomib in pre ...... with response and neuropathy.
@en
Single-agent bortezomib in pre ...... with response and neuropathy.
@nl
prefLabel
Single-agent bortezomib in pre ...... with response and neuropathy.
@en
Single-agent bortezomib in pre ...... with response and neuropathy.
@nl
P2093
P2860
P50
P356
P1476
Single-agent bortezomib in pre ...... with response and neuropathy.
@en
P2093
Anne Louise Oaklander
Anthony A Amato
Asher A Chanan-Khan
Constantine Mitsiades
David E Avigan
David J Kuter
Deborah Doss
Dixie-Lee Esseltine
Edie Weller
Hani Hassoun
P2860
P304
P356
10.1200/JCO.2008.18.3087
P407
P577
2009-06-15T00:00:00Z